# Sources — Hubert H. Humphrey

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 3, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. TIME. “Medicine: H.H.H.’s Cystectomy,” October 18, 1976. Supports the 1968 removal of several pinhead-size nonmalignant bladder growths; the 1973 finding of possibly cancerous tissue treated with thiotepa and X-ray therapy, five minutes a day for five weeks; three years free of cancer; a low-grade malignancy found at the National Naval Medical Center in Bethesda on examination for urinary tract infection symptoms; and the six-hour radical cystectomy at Memorial Sloan-Kettering Cancer Center that removed the bladder, prostate, lymph nodes, surrounding fatty tissue, and part of the urethra, with a conduit made from small intestine brought out to the right of the navel. It reports that the nodes were to be examined and that an experimental two-drug chemotherapy might be offered. https://time.com/archive/6879845/medicine-h-h-h-s-cystectomy/
2. Associated Press. “Scientists find genetic flaw that killed Hubert Humphrey.” *Deseret News*, May 5, 1994. Supports that he sought medical advice in 1967 for blood in his urine, that some doctors suspected bladder cancer while others disagreed and he was not treated, and that a 1994 study found a p53 mutation in bladder cells from a 1967 urine sample. https://www.deseret.com/1994/5/5/19107106/scientists-find-genetic-flaw-that-killed-hubert-humphrey/
3. Hruban RH, van der Riet P, Erozan YS, Sidransky D. “Brief report: molecular biology and the early detection of carcinoma of the bladder — the case of Hubert H. Humphrey.” *N Engl J Med* 1994;330(18):1276–8 (PMID 7993407). Title-level record only; PubMed has no abstract and the article was not read. https://pubmed.ncbi.nlm.nih.gov/7993407/
4. TIME. “Milestones, Aug. 29, 1977.” Supports that his cancerous bladder was removed the previous October, and that in August 1977 a malignant tumor on the pelvic bone was found at a four-hour operation in Minneapolis for a bowel obstruction, described as inoperable and terminal, with chemotherapy planned. https://time.com/archive/6849103/milestones-aug-29-1977/
5. TIME. “The Nation: The Indomitable Senator Returns,” November 7, 1977. Used only for his return to the Senate eleven weeks after the pelvic recurrence was found and for the further chemotherapy scheduled. https://time.com/archive/6881048/the-nation-the-indomitable-senator-returns/
6. *Scribner Encyclopedia of American Lives, Thematic Series: The 1960s*, “Humphrey, Hubert Horatio, Jr.” (Encyclopedia.com). Supports his birth on 27 May 1911 in Wallace, South Dakota, and his death on 13 January 1978 in Waverly, Minnesota. https://encyclopedia.com/humanities/encyclopedias-almanacs-transcripts-and-maps/humphrey-hubert-horatio-jr
7. United States Senate. “Hubert H. Humphrey: A Featured Biography.” Supports his Senate service from 1949 to 1964, as vice president from 1965 to 1969, his return to the Senate in 1971, and his death on January 13, 1978. https://www.senate.gov/senators/FeaturedBios/Featured_Bio_HumphreyHubert.htm
8. Wikipedia. “Hubert Humphrey.” Used only for the date he resumed his Senate duties after the operation (January 5, 1977). https://en.wikipedia.org/wiki/Hubert_Humphrey
9. HISTMED Master Roster v3. Internal project source. Its clinical claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. Holzbeierlein J, et al. “Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024).” *J Urol* 2024;212(1):3–10 (PMID 38661067). Adjuvant therapy for pT3 to pT4 or node-positive disease only; cross-sectional imaging of the chest, abdomen, and pelvis every 6 to 12 months for 2 to 3 years, then yearly; upper-tract, kidney function, metabolic, and vitamin B12 monitoring after urinary diversion; urethral surveillance when the urethra is retained and at high risk. The 2020 amendment named in the brief is carried forward in this 2024 version. https://pubmed.ncbi.nlm.nih.gov/38661067/
2. Holzbeierlein JM, et al. “Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.” *J Urol* 2024;211(4):533–538 (PMID 38265030). High-risk disease, carcinoma in situ, and early radical cystectomy for disease that recurs after intravesical therapy. https://pubmed.ncbi.nlm.nih.gov/38265030/
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Bladder Cancer. Surveillance after cystectomy and survivorship. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417
4. Trautner BW, et al. “IDSA 2025 Guideline Update on Complicated Urinary Tract Infections.” Infectious Diseases Society of America, July 2025. Five to seven days of a fluoroquinolone for a patient who improves; avoid a fluoroquinolone for empiric treatment after exposure in the past 12 months. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/
5. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), urologic cancer monograph: after cystectomy, CT of the chest and abdomen and pelvis every 6 to 12 months for 2 to 3 years, then yearly; renal function and upper-tract imaging every 6 months through year 3; chemistry for acid-base every 3 to 6 months early after diversion, then yearly; vitamin B12 yearly from 2 to 3 years after an ileal diversion; urethral wash cytology if the urethra is retained and at risk; ostomy care and sexual function. https://patrickrutledge.github.io/topthirty/
6. Centers for Medicare & Medicaid Services. Medicare Wellness Visits. https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html
7. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/
8. U.S. Preventive Services Task Force: A and B recommendations; colorectal cancer screening (2021); statin use for primary prevention (2022); hepatitis C screening (2020); depression and suicide risk screening (2023); unhealthy alcohol use (2018); falls prevention in older adults (2024). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
9. Centers for Disease Control and Prevention. Adult Immunization Schedule by Age. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html

## Editorial resolutions

- **Recent-death rule.** Humphrey died in 1978, so the recent-death rule does not apply. The record still attributes no statement or health fact to a relative or to a named physician: the surgeon’s and the spouse’s remarks quoted in the TIME reports are not used, and an oral history by another public figure that dates the operation to a specific day is not used.
- **Clinical, not political.** The record is clinical. His public career appears only in the timeline and as a synthetic occupation (“a demanding public job”). The political content of the 1977 TIME report is not used.
- **Tobacco.** No reliable source was found for his tobacco use; a trivia page that calls him a heavy smoker was not used. The record states only that he reports no current use and that his past history is not recorded, and lung cancer and aortic aneurysm screening are recorded as due, pending that history. A reviewer may want to source this or leave it as is.
- **Index age and dates.** The modern episode presents Humphrey at 65, three months after his radical cystoprostatectomy. The synthetic date of birth is May 27, 1960 (shift 49 years). The resection on September 2, the staging CT on September 16, and the cystoprostatectomy on October 7, 2025 map to September and October 1976; the documented month of the operation is October 1976, and the day is synthetic. The index visit on January 6, 2026 maps to January 6, 1977, the week he resumed his Senate duties, which fits the synthetic note that he is back at full-time work. The chronic-care visits on February 3, April 7, and July 7, the sick visit on March 17, and the annual wellness visit on June 2, 2026 map to the same days of 1977. All visits fall before August 1977, when the inoperable pelvic recurrence was found. He turns 66 on May 27, so the wellness visit is at 66 and is `annual_wellness_subsequent` (index age 65).
- **Documented course and the synthetic pathway.** The documented history (benign growths, then thiotepa and X-ray therapy, three years free of cancer, a low-grade malignancy, and then radical cystectomy with a small-intestine conduit) is used in the past medical history and the referral. The modern pathway is chosen to fit: recurrent multifocal low-grade papillary tumors with high-grade carcinoma in situ in a small, irradiated bladder, which in current practice supports early cystectomy, with upstaging to pT2a at cystectomy, 0 of 18 nodes, and negative margins. The grade, stage, node count, and margins are synthetic; the node result was not reported in the fetched sources. No adjuvant therapy is given, which current guidelines support for pT2a N0. TIME reported that an experimental two-drug chemotherapy might be offered after the operation; whether he received treatment before August 1977 was not found in a fetched source, and the record makes no claim about it.
- **Later recurrence.** His pelvic recurrence ten months after the operation is documented and is recorded as a claim and in the timeline, but the synthetic episode ends before it. To avoid a synthetic result that would read against the documented course, the episode contains no post-operative cross-sectional imaging: the first surveillance CT is recorded as due at one year after surgery, which is within the 6-to-12-month interval the guideline allows for pT2 N0 disease. The six-month renal ultrasound looks only for hydronephrosis. Reviewers may prefer to shorten the CT interval to six months, but that would place a synthetic negative scan about four months before the documented recurrence.
- **Sick visit.** The unscheduled visit on March 17, 2026 (true frame March 17, 1977) is a synthetic acute right pyelonephritis with *Escherichia coli* and mild acute kidney injury, treated with seven days of oral ciprofloxacin. It was chosen because upper-tract infection is a common complication of an ileal conduit, and because it teaches the difference between expected bacteriuria in conduit urine and a true infection, with a culture taken by catheter through the stoma. TIME reports urinary tract infection symptoms before the 1976 diagnosis; the synthetic infection is after the operation and does not echo a documented illness.
- **Annual wellness visit.** Judgment calls: (1) the synthetic AUDIT-C of 2 (an occasional social drink) is not drawn from a source; (2) a statin was discussed at about 14 percent ten-year risk as a current non-smoker, with no additional USPSTF risk factor, and he chose to revisit it; (3) colonoscopy four years earlier and a negative hepatitis C screen are synthetic history; (4) advance care planning names an unnamed health care agent and records only general priorities; (5) erectile dysfunction after cystoprostatectomy is recorded plainly as an expected effect of the operation, with no treatment wanted.
- **Focused visits.** The three chronic-care follow-ups (four weeks, three months, and six months after the first visit, that is four, six, and nine months after surgery) are documented as focused visits on the AUA/ASCO/SUO muscle-invasive guideline and the CMID urologic cancer monograph. Each lists every item the protocol calls for at that point, with its interval and status. The first is the same day as the urology consultation. One protocol deviation is recorded instead of an invented result: the creatinine recheck planned one week after the sick visit was not done. At the next visit, creatinine was 1.15 mg/dL, near the baseline of 1.12, so no harm is judged to have resulted; rechecks are now booked before he leaves the clinic. Synthetic findings introduced: appliance leaks with irritant peristomal dermatitis from a skin crease, corrected with a convex wafer; mild hyperchloremic metabolic acidosis (bicarbonate 20 mmol/L) treated with sodium bicarbonate and corrected to 24 mmol/L. Routine urine cultures, urethral wash cytology, and adjuvant therapy are recorded as not indicated, with the reason.
- **Consultation.** The urology referral and the consultation by Elaine Kowalczyk, MD (a fictional consultant), with a wound, ostomy, and continence nurse, on the day of the first focused visit, are **S**. The consultant answers the six referral questions with what the record shows happened afterwards: no adjuvant therapy; CT with a urographic phase at one year and then every 6 to 12 months; a renal ultrasound at six months; chemistry every 3 to 6 months with sodium bicarbonate for a bicarbonate below 22 mmol/L; a convex wafer and night drainage; no treatment of bacteriuria without symptoms and a catheter culture through the stoma for fever or flank pain; and no routine urethral cytology. The examination is consistent with Dr. Brandvold’s same-day note.
- **Not used.** The day of the operation given in an oral history, a 1974 hospital admission for tests reported in the Chicago Tribune (not fetched), the p53 study beyond its title, the details of his final months, and a search summary that suggested his cancer had returned by the end of 1976 (no fetched source said so) are not used. His height is not recorded in a fetched source; the 180 cm in the record is synthetic.
